IP Library › Granted Patent US 12,545,917
Granted Patent B1
US 12,545,917 · App. 18/891,235 · Granted Feb 10, 2026

Composition for regulating production of interfering ribonucleic acid

Inventor: Bradley G. Thompson (Calgary, CA)
Assignee: Wyvern Pharmaceuticals Inc.
C12N15/1138A61K35/76C12N15/86C12N2310/141C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,545,917
App. No.
18/891,235
Granted
Feb 10, 2026
Kind
B1
Abstract

The embodiments of the present disclosure relate to one or more compositions or methods that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule, such as CXCR5. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA. Decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions may address the afflictions experienced by the subject due to expression of the target biomolecule.

Claims (4)

1 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is SEQ ID NO: 2.

2 . The composition of claim 1 , wherein the RP is encapsulated in a protein coat, a lipid vesicle, or any combination thereof.

3 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is SEQ ID NO. 3.

4 . The composition of claim 3 , wherein the RP is encapsulated in a protein coat, a lipid vesicle, or any combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2025
From: THOMPSON, BRADLEY G.
To: WYVERN PHARMACEUTICALS INC.
Reel/Frame 073057/0729 →
References Cited (39)
US 11085055B2 · Mallol et al. · 2021 [cited by applicant]
US 11162102B2 · Minshull et al. · 2021 [cited by applicant]
US 11530423B1 · Thompson · 2022 [cited by applicant]
US 11873505B2 · Thompson · 2024 [cited by applicant]
US 12018274B2 · Thompson · 2024 [cited by applicant]
US 12134770B1 · Thompson · 2024 [cited by applicant]
US 20240026377A1 · Thompson · 2024 [cited by applicant]
CA 2721333A1 · 2009 [cited by applicant]
Hughes et al. The FEBS journal vol. 285, 16 (2018): 2944-2971 (Year: 2018). [cited by examiner]
O'Brien et al. Frontiers in endocrinology vol. (2018), 9:402 (Year: 2018). [cited by examiner]
Lu et al. Carcinogenesis vol. 35,3 (2013) p. 554-563 (Year: 2013). [cited by examiner]
Ren et al. Biological & pharmaceutical bulletin vol. 43,5 (2020): p. 810-816 (Year: 2020). [cited by examiner]
Lam JK, Chow MY, Zhang Y, Leung SW. siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther Nucleic Acids. 2015; 4(9):e252. Published Sep. 15, 2015. doi: 10.1038/mtna.2015.23 (Year: 2015). [cited by examiner]
Ying SY, Chang DC, Lin SL. The microRNA (miRNA): overview of the RNA genes that modulate gene function. Mol Biotechnol. 2008;38(3):257-268. doi: 10.1007/s12033-007-9013-8 (Year: 2008). [cited by examiner]
Van den Berg FT, Rossi JJ, Arbuthnot P, Weinberg MS. Design of Effective Primary MicroRNA Mimics With Different Basal Stem Conformations. Mol Ther Nucleic Acids. 2016;5(1):e278. Published Jan. 12, 2016. doi: 10.1038/mtn… [cited by examiner]
Denzler R, McGeary SE, Title AC, Agarwal V, Bartel DP, Stoffel M. Impact of MicroRNA Levels, Target-Site Complementarity, and Cooperativity on Competing Endogenous RNA-Regulated Gene Expression. Mol Cell. 2016;64(3):565… [cited by examiner]
Gorski SA, Vogel J, Doudna JA. RNA-based recognition and targeting: sowing the seeds of specificity. Nat Rev Mol Cell Biol. 2017;18(4):215-228. doi: 10.1038/nrm.2016.174 (Year: 2017). [cited by examiner]
O'Brien et al. “Overview of microRNA biogenesis, mechanisms of actions, and circulation.” Frontiers in endocrinology 9 (2018): 402. [cited by applicant]
Gorski et al. “RNA-based recognition and targeting: sowing the seeds of specificity.” Nature Reviews Molecular Cell Biology 18.4 (2017): 215-228. [cited by applicant]
Bottoni et al. “Targeting BTK through microRNA in chronic lymphocytic leukemia.” Blood, The Journal of the American Society of Hematology 128.26 (2016): 3101-3112. [cited by applicant]
Christensen et al. “Recombinant adeno-associated virus-mediated microRNA delivery into the postnatal mouse brain reveals a role for miR-134 in dendritogenesis in vivo.” Frontiers in neural circuits 3 (2010): 848. [cited by applicant]
Bofill-De Ros et al. “Guidelines for the optimal design of miRNA-based shRNAs.” Methods 103 (2016): 157-166. [cited by applicant]
Denzler et al. “Impact of microRNA levels, target-site complementarity, and cooperativity on competing endogenous RNA-regulated gene expression.” Molecular cell 64.3 (2016): 565-579. [cited by applicant]
Van Den Berg et al. “Design of effective primary microRNA mimics with different basal stem conformations.” Molecular Therapy Nucleic Acids 5 (2016). [cited by applicant]
Tritschler et al. “Concepts and limitations for learning developmental trajectories from single cell genomics.” Development 146.12 (2019): dev170506. [cited by applicant]
Ahmadzadeh et al. “BRAF mutation in hairy cell leukemia.” Oncology reviews 8.2 (2014): 253. [cited by applicant]
Patton et al. “Biogenesis, delivery, and function of extracellular RNA.” Journal of extracellular vesicles 4.1 (2015): 27494. [cited by applicant]
Clark et al. “Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies.” Oncotarget 11.44 (2020): 4016. [cited by applicant]
Wang et al. “Adeno-associated virus vector as a platform for gene therapy delivery.” Nature reviews Drug discovery 18.5 (2019): 358-378. [cited by applicant]
Kondratov et al. “Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells.” Molecular Therapy 25.12 (2017): 2661-2675. [cited by applicant]
Nature (2010. Gene Expression. Scitable. Available online at Nature.com) <https://www.nature.com/scitable/topicpage/gene-expression-14121669> (2010). [cited by applicant]
Brutons Tyrosine Kinase Genbank Sequence (2023). [cited by applicant]
GenBank EGFR Sequence (2023). [cited by applicant]
GenBank EGF Sequence (2023). [cited by applicant]
NCBI search results for SEQ ID No. 5 (2024). [cited by applicant]
NCBI Nucleotide Sequence ALK Lingand, search performed Dec. 26, 2024 (2023). [cited by applicant]
NCBI Nucleotide Sequence ALK Receptor, search performed Dec. 26, 2024 (2023). [cited by applicant]
NCBI Nucleotide Sequence for PARP, search performed Dec. 26, 2024 (2024). [cited by applicant]
GenBank FLT3 Sequence (2024). [cited by applicant]